44th week of 2015 patent applcation highlights part 10 |
Patent application number | Title | Published |
20150306130 | CHITOSAN COVALENTLY LINKED WITH SMALL MOLECULE INTEGRIN ANTAGONIST FOR TARGETED DELIVERY - The invention relates to the chitosan polymer derivatives of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Y, X | 2015-10-29 |
20150306131 | OXIDATITIVE PHOTOACTIVATED SKIN REJEUVENATION COMPOSITION COMPRISING HYALURONIC ACID, GLUCOSAMINE, OR ALLANTOIN - There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier. | 2015-10-29 |
20150306132 | COMPOSITION AND METHOD TO ALLEVIATE JOINT PAIN USING A MIXTURE OF FISH OIL AND FISH OIL DERIVED, CHOLINE BASED, PHOSPHOLIPID BOUND FATTY ACID MIXTURE INCLUDING POLYUNSATURATED EPA AND DHA - Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found using a mixture of fish oil and fish oil derived, choline based, phospholipid bound fatty acid mixture including polyunsaturated EPA and DHA either alone or in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form. | 2015-10-29 |
20150306133 | Ligneous plant-derived heteropolysaccharides for use in treatment of urologic symptoms and diseases - The present invention relates to preventing and/or treating urologic diseases and symptoms in humans or domestic animals. The present invention relates also to preventing and/or treating pain in the pelvic area. The invention relates to use of a heteropolysaccharide composition isolated from ligneous plants and comprising hemicelluloses, mainly glucomannans, but also xylans and pectic polysaccharides, as well as fractions, subgroups or mixtures of these, as pharmaceutical preparations, food additives and food products. | 2015-10-29 |
20150306134 | APPLICATION OF MALTOTRIOSE-COATED 4TH GENERATION POLYPROPYLENEIMINE DENDRIMER PPI-G4-OS-MAL-III - The application of maltotriose-coated 4th generation polypropyleneimine dendrimer PPI-G4-OS-Mal-III containing 25-45% of peripheral amines groups coated with maltotriose particles to make a drug for treating neoplastic proliferation diseases, particularly chronic lymphocytic leukemia. | 2015-10-29 |
20150306135 | ORAL PHARMACEUTICAL COMPOSITION FOR DRUGS WITH A HIGH-DOSAGE REGIMEN - The present invention relates to an oral pharmaceutical composition for drugs with a high dosage regimen, specifically, ion exchange resins and bulk-forming laxatives. Said composition comprises the combination of a liquid oily component and a texturizing agent, giving the composition good organoleptic properties that allow taking drugs with a high dosage regimen without the usual problems associated with their poor palatability. The invention also relates to a method for preparing said composition and to the use thereof for the treatment of various pathologies. Furthermore, the invention also relates to an adduct formed between a polyol and an ion exchange resin, to a method for preparing it, and to the use thereof to improve resin palatability. | 2015-10-29 |
20150306136 | XENON AND/OR ARGON TREATMENT AS AN ADJUNCT TO PSYCHOTHERAPY FOR PSYCHIATRIC DISORDERS - The present invention relates generally to the fields of treating psychiatric disorders, in particular, anxiety disorders including post-traumatic stress disorder (PTSD) in subjects, e.g., human subjects, by administering a xenon and/or argon containing composition. Treatments can also employ psychotherapy in combination with administration of xenon and/or argon, alone or in combination with additional psychotherapeutic medications to treat the anxiety disorder and reduce a symptom of the anxiety disorder in the subject. | 2015-10-29 |
20150306137 | METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION - Provided is a method for preventing or treating inflammation and associated states (e.g. infection, hypersensitivity, pain) by administering a therapeutically effective amount of an oxidative reduction potential (ORP) water solution that is stable for at least about twenty-four hours. The ORP water solution administered in accordance with the invention can be combined with one or more suitable carriers and can be administered in conjunction with one or more additional therapeutic agents. | 2015-10-29 |
20150306138 | TREATMENT OF TRAUMATIC BRAIN INJURY BY USING GALLIUM COMPOUNDS TO REDUCE OXIDATIVE STRESS LEVELS - The method for treating traumatic brain injury in an individual includes the step of administering a therapeutically effective amount of a pharmaceutically acceptable gallium compound to a blood brain barrier of the individual within a therapeutically effective time period subsequent to the injury so as to reduce secondary injury in a brain of the individual. Secondary injuries include swelling of the brain after the initial injury, secondary lesions, hematomas, and edema. The effective amount and effective time period for the step of administering are established by test results disclosed in the present invention. Gallium compounds are shown to reduce oxidative stress levels in the brain, a metric for treatment of traumatic brain injury or concussion. | 2015-10-29 |
20150306139 | ANTI-INFLAMMATORY AGENTS - This invention concerns anti-inflammatory agents and methods for treating inflammatory disorders. Also disclosed are methods for identifying or evaluating anti-inflammatory agents or compositions. | 2015-10-29 |
20150306140 | INDUCED ACTIVATION IN DENDRITIC CELLS - The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide. | 2015-10-29 |
20150306141 | METHOD AND COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY - The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described. | 2015-10-29 |
20150306142 | USE OF COMMON GAMMA CHAIN CYTOKINES FOR THE VISUALIZATION, ISOLATION AND GENETIC MODIFICATION OF MEMORY T LYMPHOCYTES - It is described in vitro methods for expanding, detecting or isolating rare populations of antigen specific memory T cells. It is also described an in vitro method for obtaining a genetically modified memory T cell population. Uses of cells so obtained are also disclosed. | 2015-10-29 |
20150306143 | COMPOSITIONS FOR TREATING AN INFLAMMATORY AUTOIMMUNE CONDITION - The present invention relates to a medicament comprising human Tr1 cells directed to a human HSP and methods for treating an inflammatory autoimmune condition. | 2015-10-29 |
20150306144 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of | 2015-10-29 |
20150306145 | ALLOGENIC MESENDRITIC VECTOR FOR OVARIAN CANCER - The present invention recommends a new approach of allogenic dendritic-stem cell vaccine platform to treat all kinds of ovarian cancers. It proposes the abundant allogenic donated cord blood source to harvest both dendritic special type and mesenchymal stem cells equilibrated package primed with patient's tumour antigens for a targeted treatment regime. The individual roles of dendritic cells and mesenchymal stem cells in immunomodulation is exploited in developing this new combinatorial platform of cellular vectors for targeted killing of tumour cells in the patient's body. The source proposed here in developing the technology is a biological discard and is available in profusion for proposed clinical application. | 2015-10-29 |
20150306146 | METHODS OF TREATING OR PREVENTING RESPIRATORY CONDITIONS - The present disclosure provides methods of treating or preventing respiratory condition and/or for treating an IgE-mediated allergy and/or for reducing an allergic response to an allergen and/or for inducing anergy to an allergen in a subject and/or improving lung function in a subject suffering from an allergy comprising administering to a subject a population of cells enriched for STRO-1 | 2015-10-29 |
20150306147 | ISOLATED LIVER STEM CELLS - A method of treating liver-based inborn, metabolic deficiencies is disclosed by treatment of an individual, such as a patient suffering from liver-based inborn, metabolic deficiencies, with human progenitor or stem cells, a cell population or their progeny. The cells used in the treatment have the following characteristics. They are positive for vimentin, α-smooth muscle actin (ASMA), and for at least one mesenchymal marker such as CD90, CD29, CD73, and CD44. They are positive for at least one hepatocyte marker such as albumin, alpha-fetoprotein, alpha-1 antitrypsin, HNF-4 and MRP2 transporter. They express at least one hepatocyte-like property or function such as G6P, CYP1B1, CYP3A4, TDO, TAT, GS, GGT, CK8, and EAAT2. They are negative for at least one marker such as cytokeratin-19, CD45, CD34, CD49f, CD133, HLA-DR, and CD117. They have mesenchymal-like morphology. They originate from human adult liver cells. | 2015-10-29 |
20150306148 | COMPOSITIONS AND METHODS RELATED TO ORGAN OR TISSUE DECELLULARIZATION - Embodiments include methods for decellularizing an organ or tissue comprising conditioning the organ or tissue to be decellularized by exposing the organ or tissue to electricity, as well as methods of using such decellularized organs or tissues. | 2015-10-29 |
20150306149 | Methods for Modulating Inflammatory Responses - The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents. | 2015-10-29 |
20150306150 | TREATMENT OF BONE-RELATED CANCERS USING PLACENTAL STEM CELLS - Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer. | 2015-10-29 |
20150306151 | POLARIZED SCORPION VENOM SOLUTION AND A METHOD FOR MAKING POLARIZED SCORPION VENOM SOLUTION - The present invention discloses a polarized dilute blue scorpion venom solution and a method for administering dilute scorpion venom solution. The polarized dilute scorpion venom solution provides treatment to various diseases and conditions such as relieving pain, improving immune-system responses, treating cancer, preventing cancer, improving quality of sleep, reducing inflammation, and minimizing negative biological response to chemotherapy and radiation treatment | 2015-10-29 |
20150306152 | USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS - The present invention relates to | 2015-10-29 |
20150306153 | Mixture, Dissolving Solution and Pharmaceutical Agent Each Comprising Thermophilic Microorganism - To provide a mixture, a dissolving solution and a pharmaceutical agent, which contain a thermophilic microorganism to make it possible to regulate a mucous membrane immune system gene cluster and metabolism-related gene clusters of the intestines and the liver. Each of them is prepared by fermentation of an organic material containing a thermophilic microorganism at a temperature of 50° C. or more and 90° C. or less. By being administered to the animal, it regulates at least one of a mucous membrane immune system gene cluster, a metabolism-related gene cluster in the intestines, and a metabolism-related gene cluster in the liver of the animal. The microorganism includes at least one species of the genus | 2015-10-29 |
20150306154 | STRAINS AND METHODS USEFUL FOR MYCOTOXINS - The disclosure relates to strains, compositions and methods for detoxifying a mycotoxin. In another embodiment, the disclosure relates to strains, compositions and methods for alleviating the gastrointestinal inflammatory response resulting from ingestion of mycotoxins. In one embodiment, the strains are | 2015-10-29 |
20150306155 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic | 2015-10-29 |
20150306156 | PROBIOTIC RECOLONISATION THERAPY - The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic | 2015-10-29 |
20150306157 | LACTIC ACID BACTERIUM FOR PROPHYLAXIS OR TREATMENT OF A STRESS-INDUCED DISORDER AND A COMPOSITION CONTAINING THE SAME - The present invention provides an isolated lactic acid bacterium, | 2015-10-29 |
20150306158 | LACTIC ACID BACTERIA CAPABLE OF PREVENTING AND/OR TREATING SENESCENCE AND DEMENTIA - The present invention provides a novel lactic acid bacterium having antioxidant and anti-aging functions and a dementia alleviation effect, and more specifically, provides | 2015-10-29 |
20150306159 | Method for Prevention and Treatment of Streptococcus Parauberis Infections - A composition includes an isolated bacteriophage Str-PAP-1 having the ability to kill | 2015-10-29 |
20150306160 | ONCOLYTIC ADENOVIRUS ARMED WITH THERAPEUTIC GENES - The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway. | 2015-10-29 |
20150306161 | EDIBLE COMPOSITION. - The present invention provides relates to an edible composition for anti-diabetic benefit. Diabetes is one of the major and commonly occurring health problems in today's world. Pharmaceuticals companies are very active in this field to develop new medicines for preventing and controlling diabetes. There are several medicines available in the market for the treatment of type 2 diabetes. There are also prior arts which describes composition for the prevention of glucose intolerance and/or diabetes. We have found that though prior that discloses compositions for prevention of glucose intolerance and/or diabetes, it is not that effective for preventing diabetes. The present inventors while working extensively for providing an edible composition for preventing diabetes have surprisingly found that a particular combination of | 2015-10-29 |
20150306162 | USE OF A COMPOSITION COMPRISING ARABIC GUM (AG) FOR IMPROVING GUT IMPERMEABILITY - A method for improving gut impermeability including administering to a subject a sufficient amount of a composition comprising | 2015-10-29 |
20150306163 | PREVENTION AND TREATMENT OF DISORDERS CONNECTED TO IMPAIRED NEUROTRANSMISSION - The present invention relates to the use of rosemary extracts for the prevention and treatment of disorders connected to impaired neurotransmission such as depression in humans, companion animals and farm animals. | 2015-10-29 |
20150306164 | USES OF BACOPA MONNIERI EXTRACT - The present invention broadly relates to methods for acutely improving/enhancing cognitive performance in a human subject comprising administration of an extract of | 2015-10-29 |
20150306165 | PLANT EXTRACT COMPOSITION FOR INHIBITING ADIPOCYTES, REDUCING BODY FAT, PROMOTING WEIGHT LOSS AND INCREASING LIPID METABOLISM AS WELL AS APPLICATION THEREOF - The present invention provides a plant extract composition for inhibiting adipocytes, reducing body fat, losing body weight or increasing lipid metabolism, wherein the composition comprises 1.5 wt % to 40 wt % of resveratrol and 10 wt % to 85 wt % green tea extract. The composition not only provides high safety, but also effectively suppresses preadipocytes, inhibits differentiating adipocytes, inhibits mature adipocytes, increases the activity of carnitine acyl transferase-1, decreases body fat and promotes weight loss, and regulates the expression of the leptin gene and resistin gene. | 2015-10-29 |
20150306166 | ANTIMICROBIAL & ANTIVIRAL COMPOSITION - A method of reducing the number of microorganisms entering the nose and proliferating in the nasal cavity including application of a solution of an antimicrobial, antiviral and antifungal composition to the anterior vestibular region of the nares. The antimicrobial, antiviral and antifungal solution includes ethyl alcohol as an active ingredient. Various embodiments may also include one or more of the following additional ingredients: orange oil, coconut oil; soy oil; emu oil; grapefruit seed extract; glycine soja; | 2015-10-29 |
20150306167 | ALPINIA SPP. EXTRACTS FOR TREATING IRRITABLE BOWEL SYNDROME - Disclosed herein is the use of an extract from | 2015-10-29 |
20150306168 | METHODS OF PROTECTING AGAINST APOPTOSIS USING LIPOPEPTIDES - The use of lipopeptides as inducers of NF-κB for the protection of mammals from the effects of apoptosis is described. | 2015-10-29 |
20150306169 | METHOD AND COMPOSITIONS FOR SYNCHRONIZING TIME OF INSEMINATION IN GILTS - Methods and compositions for synchronizing the time of insemination in gilts are provided. More particularly, methods and compositions for synchronizing the time of insemination in gilts using a gonadotropin-releasing hormone and a hormone for synchronizing estrus are provided. | 2015-10-29 |
20150306170 | COMPOSITION FOR IMMEDIATE AND EXTENDED RELEASE - The subject invention relates to fast dissolving pharmaceutical compositions comprising an active ingredient for immediate release and further comprising a controlled release dosage form comprising an active ingredient for controlled release. | 2015-10-29 |
20150306171 | THERAPEUTIC AGENT COMPOSITION AND METHOD OF USE - The invention relates to the use of cyclic Prolyl Glycine (“cyclic PG” or “cPG”) and analogs and mimetics thereof, as neuroprotective agents for the treatment and or prevention of neurological disorders including but not limited to cerebral ischemia or cerebral infarction resulting from a range of phenomena, such as thromboembolic or hemorrhagic stroke, cerebral basospasms, hypoglycemia, cardiac arrest, status epilepticus, perinatal asphyxia, anoxia such as from drowning, pulmonary surgery, and cerebral trauma, as well as to the treatment and prevention of chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, and as anticonvulsants. | 2015-10-29 |
20150306172 | CYCLIC PEPTIDES AND USE AS MEDICINES - The present invention provides a compound of formula I; | 2015-10-29 |
20150306173 | PHOSPHOLIPID DEPOT - The present invention provides a clear depot comprising at least one hydrophilic water-soluble pharmaceutically active agent selected from the group consisting of vancomycin, gentamicin, a pharmaceutically acceptable salt thereof and a mixture thereof, water, a phospholipid, an oil, optionally a pH adjusting agent, and a viscosity modifying agent selected from the group consisting of ethanol, isopropanol, and a mixture thereof, wherein the water present in the depot is no more than about 4 wt % relative to the total weight of the depot and the depot has a pH of between about 3 and about 6, method of making and administering same. | 2015-10-29 |
20150306174 | Trimeric HIV Fusion Inhibitors for Treating or Preventing HIV Infection - Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif. | 2015-10-29 |
20150306175 | HSP For Use in Treatment for Imiquimod Related Side Effects - The invention relates to a healthcare product comprising (i) a component selected from the group of heat shock proteins from alfalfa and heat shock protein hydrolysates from alfalfa, the product further comprising imiquimod or a pharmaceutically acceptable salt or derivative thereof. Further, the invention relates to a healthcare product for use in the prophylactic or therapeutic treatment of a skin disorder. Further, the invention relates to HSP for use for use in preventing the occurrence of a negative-side effect of a treatment with imiquimod, or alleviating such side effect. | 2015-10-29 |
20150306176 | RECONSTITUTED HDL FORMULATION - The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form. | 2015-10-29 |
20150306177 | THERAPY FOR RADIATION-INDUCED LUNG INJURY - Methods are disclosed for therapy of radiation-induced lung injury and other lung diseases using R-spondin | 2015-10-29 |
20150306178 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING TINNITUS - The invention relates to pharmaceutical compositions and methods for treating inner ear disorders. In particular, the invention provides a method for treating and/or preventing acute inner ear tinnitus in a subject in need thereof by administering a pharmaceutical composition comprising a peptide inhibitor of c-Jun N-terminal kinase. | 2015-10-29 |
20150306179 | CONCENTRATED PROTEIN PREPARATIONS OF BONE MORPHOGENETIC PROTEINS AND METHODS OF USE THEREOF - Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7. | 2015-10-29 |
20150306180 | GM-CSF FOR USE IN THE PREVENTION OF SPONTANEOUS ABORTION AND EMBRYO IMPLANTATION FAILURE - The invention relates to GM-CSF for use in a method for the prevention of spontaneous abortion in a subject suffering from recurrent miscarriage, comprising administering to said subject an effective amount of GM-CSF as sole active substance, wherein said method also prevents or reduces the likelihood of embryo implantation failure in the subject undergoing an assisted reproduction procedure. | 2015-10-29 |
20150306181 | DELIVERY OF BIOTHERAPEUTICS TO THE BRAIN - Compositions and methods for delivering therapeutic compounds to the brain are provided. | 2015-10-29 |
20150306182 | FAT LOSS COMPOSITION - Disclosed is a fat loss composition comprising a) a prostaglandin F2alpha analogue, such as cloprostenol, or a pharmaceutically acceptable ester or salt thereof; and b) amino acids 176-191 of human growth hormone. Use of the composition in weight loss, weight management and/or slimming is described. | 2015-10-29 |
20150306183 | FIVE-COORDINATE NEUROGLOBIN AND USE THEREOF AS A BLOOD SUBSTITUTE - Described herein is the finding that a mutant form of human neuroglobin (H64L) with a stable five-coordinate geometry reduces nitrite to nitric oxide approximately 2000-times faster than the wild type neuroglobin. Five-coordinate neuroglobin is also capable of binding and releasing oxygen. Based on these findings, the use of five-coordinate neuroglobin as a blood substitute is described herein. Particularly provided is a method of replacing blood and/or increasing oxygen delivery to tissues in a subject by administering to the subject a therapeutically effective amount of neuroglobin with a stable five-coordinate geometry. In some cases, five-coordinate neuroglobin is administered in combination with another therapeutic agent or composition, such as a second blood replacement product (for example, a hemoglobin-based oxygen carrier), a blood product (such as red blood cells, serum or plasma) or whole blood. | 2015-10-29 |
20150306184 | Tumor-Specific Delivery of Therapeutic Agents via Liposomase/US - is an obligate anaerobe that can infect hypoxic regions within experimental tumors. We found that mice bearing large, established tumors were often cured when treated with | 2015-10-29 |
20150306185 | HEPARANASE AND ITS USES RELATED TO EXOSTOSES - Methods of treating or preventing exostosis in a subject comprising administering to a subject with exostosis or at risk of developing exostosis an effective amount of an agent that that cleaves heparan sulfate or an agent that increases expression of an enzyme that cleaves heparan sulfate are provided herein. | 2015-10-29 |
20150306186 | PROCESS FOR PRODUCTION AND PURIFICATION OF RECOMBINANT LYSOSOMAL ALPHA-MANNOSIDASE - The present invention relates to a process for purification of recombinant alpha-mannosidase, a process for production of alpha-mannosidase, a composition comprising alpha-mannosidase, use of the composition as a medicament, use as a medicament for the treatment of alpha-mannosidosis and a method of treating alpha-mannosidosis and/or alleviating the symptoms of alpha-mannosidosis. | 2015-10-29 |
20150306187 | SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A - The invention relates, in part, to improved methods of administering α-galactosidase A for the treatment of α-galactosidase A deficiencies including Fabry disease. | 2015-10-29 |
20150306188 | TREATMENT OF HEADACHE BY INJECTION OF NEUROINHIBITORY SUBSTANCE TO SPHENOPALATINE GANGLION OR OTIC GANGLION - A neuroinhibitory substance for use in a method for treating or preventing headache comprising injecting a neuroinhibitory substance such as botulinium toxin in close proximity to the sphenopalatine ganglion or otic ganglion wherein an injection device comprising said neuroinhibitory substance is brought into close proximity to the sphenopalatine ganglion or otic ganglion by inserting said injection device into the patient transnasally or infrazygomatically and the neuroinhibitory substance injected in close proximity to the SPG or OG. | 2015-10-29 |
20150306189 | Compositions and Methods for Inducing Liver Regeneration by Administering Hepatocyte-Derived Exosomes - A pharmaceutical composition containing (1) a therapeutically effective amount of hepatocyte-derived exosomes; and (2) a pharmaceutically-acceptable carrier is provided. Also provided herein is a method of inducing liver regeneration in a patient in need thereof, the method including administering to the patient a therapeutic amount of hepatocyte-derived exosomes, wherein liver regeneration is induced. Methods for up-regulating synthesis of synthesis of sphingosine-1-phosphate (S1P) in a hepatocyte by contacting the hepatocyte with at least one vesicle containing sphingosine kinase 2, and, optionally, ceramide and neutral ceramidase, are also disclosed. | 2015-10-29 |
20150306190 | METHODS OF DIAGNOSING AND TREATING SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND SIBO-RELATED CONDITIONS - Disclosed is a method of treating small intestinal bacterial overgrowth (SIBO) or a SIBO-caused condition in a human subject. SIBO-caused conditions include irritable bowel syndrome, fibromyalgia, chronic pelvic pain syndrome, chronic fatigue syndrome, depression, impaired mentation, impaired memory, halitosis, tinnitus, sugar craving, autism, attention deficit/hyperactivity disorder, drug sensitivity, an autoimmune disease, and Crohn's disease. Also disclosed are a method of screening for the abnormally likely presence of SIBO in a human subject and a method of detecting SIBO in a human subject. A method of determining the relative severity of SIBO or a SIBO-caused condition in a human subject, in whom small intestinal bacterial overgrowth (SIBO) has been detected, is also disclosed. | 2015-10-29 |
20150306191 | VACCINE - The present invention relates to a vaccine capable to induce the formation of antibodies directed to PCSK9 in vivo. | 2015-10-29 |
20150306192 | MODIFIED FVIII APITOPE PEPTIDES - The present invention provides peptides partly derivable from FVIII which are capable of binding to an MHC class II molecule without further antigen processing and being recognised by a factor VIII specific T cell. In particular, the present invention provides peptides comprising the sequence DNIMVTFRNQASRPY or PRCLTRYYSSFVNME with modifications at the N- and C-termini. The present invention also relates to the use of such a peptide for the prevention or suppression of inhibitor antibody formation in haemophilia A and/or acquired haemophilia. | 2015-10-29 |
20150306193 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE CONDITIONS, INCLUDING TYPE 1 DIABETES - The present invention provides a vaccine, immunogenic polypeptide, and pharmaceutical compound, all including a serpinB13 protein or polypeptide or an immunogenic polypeptide that includes a serpinB13 protein or polypeptide coupled to an immunogenic agent. The present invention further includes use of these agents according to a method of inhibiting or delaying onset, or reducing the severity of type 1 diabetes, as well as a method of treating an individual for an immune condition selected from the group of psoriasis, hair loss, and ulcers including diabetic food ulceration. | 2015-10-29 |
20150306194 | METHOD FOR TREATING A SYNUCLEIOPATHY - A method for preventing and/or treating a synucleinopathy, comprising administering a composition containing at least one mimotope of an epitope of alpha-synuclein, wherein said at least one mimotope is coupled or fused to a pharmaceutically acceptable carrier protein selected from the group consisting of a non-toxic diphtheria toxin mutant, keyhole limpet hemocyanin (KLH), diphtheria toxin (DT), tetanus toxid (TT) and | 2015-10-29 |
20150306195 | HEMOGLOBIN RECEPTOR AS NOVEL VACCINE FOR LEISHMANIASIS - The present invention in general relates Hemoglobin receptor or its part as a novel vaccine candidate against Leishmaniasis. Specifically, the present invention envisages HbR DNA for eliciting immune response in a mammal against Leishmaniasis. Additional aspect of the present invention is related to a vaccine composition for inducing immune response against Leishmaniasis in mammals. In a preferred aspect, the present invention relates to use of HbR-polypeptide as marker for diagnosis of | 2015-10-29 |
20150306196 | POLYPEPTIDE VACCINE - We provide a polypeptide vaccine for treatment and prevention of cancer, particularly prevention of metastasis of cancer. Also provided are methods of treating or preventing cancer, and pharmaceutical compositions comprising the polypeptide vaccine. | 2015-10-29 |
20150306197 | PROSTATE CANCER VACCINE - Androgen receptor-based vaccines for eliciting an immune reaction in vivo against cells expressing androgen receptor are disclosed. The vaccines are useful in the treatment of prostate cancer. Also disclosed are methods for inducing immune reaction to androgen receptor or treating prostate cancer in a mammal, using the vaccines and pharmaceutical compositions comprising the vaccines. | 2015-10-29 |
20150306198 | Aspartate- -hydroxylase Induces Epitope-specific T Cell Responses in Tumors - The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors. | 2015-10-29 |
20150306199 | Leptospira With Increased Antigenic Mass - The antigenic mass of | 2015-10-29 |
20150306200 | VECTORS FOR TRANSFORMING MYCOPLASMA HYOPNEUMONIAE, TRANSFORMED M. HYOPNEUMONIAE STRAINS, AND USE THEREOF - The present invention relates to mutant strains of | 2015-10-29 |
20150306201 | NOVEL METHOD FOR TREATING H.PYLORI INFECTIONS - The present invention is related to a polypeptide comprising an amino acid sequence, whereby the amino acid sequence of the polypeptide is at least 80% identical to a stretch of consecutive amino acids of the region of HPGGT comprising an amino acid sequence corresponding to SEQ.ID.No. 1, whereby such region is defined by
| 2015-10-29 |
20150306202 | ATTENUATED LIVE VACCINE FOR CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS AND ERVE VIRUS - The genetically modified nairoviruses of this invention possesses a viral ovarian tumor protease with decreased ability to remove ubiquitin (Ub) and ISG15 tags that the human organism uses to label proteins for removal. Exemplary are Crimean-Congo hemorrhagic fever virus and Erve virus. Unlike complete knockout strains, the modified virus retains enough activity for replication in a human cell line. This creates an immunogenic and non-pathogenic virus that can be used as an effective live vaccine agent for prophylaxis and treatment. | 2015-10-29 |
20150306203 | SYNTHETIC PEPTIDE-BASED EMERGENCY VACCINE AGAINST FOOT AND MOUTH DISEASE (FMD) - Synthetic FMD peptide immunogens and compositions containing the same are disclosed. Methods for detecting, treating, and preventing an FMD infection in an animal using the synthetic FMD peptide immunogens are also disclosed. In a specific embodiment, a peptide-based emergency vaccine and formulations thereof against Foot and Mouth Disease is described. Various vaccine formulations contain a mixture of peptides derived from FMDV VP1 protein; each peptide containing a B cell FMDV neutralizing/receptor binding epitope sequence linked to an artificial Th epitope to enhance the immunogenicity of each peptide. Disclosed vaccine formulations containing viral immunogens can optionally be supplemented with a mixture of peptides representing the FMDV endogenous Th epitopes derived from FMDV proteins, homologues and functional analogues thereof. Such viral peptide compositions are prepared in an acceptable delivery system as vaccine formulations and can provide protection pigs and cattle from infection upon FMDV challenge with only single administration. | 2015-10-29 |
20150306204 | VACCINE COMPOSITION FOR USE IN IMMUNO-COMPROMISED POPULATIONS - The invention relates to nasally-administered vaccine compositions effective against infection in immuno-compromised populations. One aspect of the invention is directed to the pediatric use of the vaccine of the invention including a vaccine effective in children against seasonal influenza virus strains. A further aspect of the invention is directed to subjects of all age groups when the composition is for pandemic use. | 2015-10-29 |
20150306205 | VACCINE COMPOSITION FOR NAIVE SUBJECTS - The invention relates to nasally-administered vaccine compositions effective in naive subjects such as children. Further, the vaccine composition is suitable for vaccinating the general population during a pandemic. One aspect of the invention is directed to the paediatric use of the vaccine of the invention including a vaccine effective in children against seasonal influenza virus strains. A further aspect of the invention is directed to subjects of all age groups when the composition is for pandemic use. | 2015-10-29 |
20150306206 | FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) - Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics. | 2015-10-29 |
20150306207 | RECOMBINANT NANOPARTICLE RSV F VACCINE FOR RESPIRATORY SYNCYTIAL VIRUS - The present invention is generally related to modified or mutated respiratory syncytial virus fusion (F) proteins and methods for making and using them, including immunogenic compositions such as vaccines for the treatment and/or prevention of RSV infection. | 2015-10-29 |
20150306208 | Soluble Forms of Hendra and Nipah Virus G Glycoprotein - This invention relates to soluble forms of G glycoprotein from Hendra and Nipah virus. In particular, this invention relates to compositions comprising soluble forms of G glycoprotein from Hendra and Nipah virus and also to diagnostic and therapeutic methods using the soluble forms of G glycoprotein from Hendra and Nipah virus. Further, the invention relates to therapeutic antibodies including neutralizing antibodies, and vaccines for the prevention and treatment of infection by Hendra and Nipah viruses. | 2015-10-29 |
20150306209 | CANINE PARVOVIRUS TYPE 2c ISOLATES AND METHODS OF USE - The present invention discloses an attenuated canine parvovirus. In addition, the present invention discloses isolated and/or recombinant canine parvovirus capsid proteins and the nucleic acids that encode the canine parvovirus capsid proteins. The present invention further discloses immunogenic compositions and/or vaccines comprising the attenuated canine parvovirus isolates, corresponding capsid proteins, and/or recombinant vectors which express nucleic acids that encode the canine parvovirus capsid proteins. | 2015-10-29 |
20150306210 | VACCINE AGAINST BETA-HERPESVIRUS INFECTION AND USE THEREOF - The present invention is related to a beta-herpesvirus, wherein the beta-herpesvirus is spread-deficient. | 2015-10-29 |
20150306211 | PROCESS FOR PRODUCING AN ALLERGEN EXTRACT - The present invention discloses processes for producing native, depigmented and polymerised allergen extracts. The invention further discloses extracts produced via the processes, and pharmaceutical and vaccine compositions comprising the extracts, for diagnosis and treatment of allergy. | 2015-10-29 |
20150306212 | SYNTHETIC MEMBRANE-RECEIVER COMPLEXES - Compositions comprising synthetic membrane-receiver complexes, methods of generating synthetic membrane-receiver complexes, and methods of treating or preventing diseases, disorders or conditions therewith. | 2015-10-29 |
20150306213 | HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS - The invention provides an immunostimulatory peptide containing the amino acid sequence SAFFLFCSE and uses thereof. | 2015-10-29 |
20150306214 | ADJUVANT FOR MUCOSAL VACCINE - An object of the present invention is to provide an adjuvant for a mucosal vaccine with high safety that induces a sufficient immune response on the mucosa. According to the present invention, an adjuvant for a mucosal vaccine comprising a protein complex composed of hemagglutinin (HA) subcomponents HA1, HA2, and HA3 of botulinum toxin is provided. | 2015-10-29 |
20150306215 | LPRG AS A CHAPERONE OF IMMUNE ADJUVANTS - An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor. | 2015-10-29 |
20150306216 | COMBINATIONS OF A PI3K/AKT INHIBITOR COMPOUND WITH AN HER3/EGFR INHIBITOR COMPOUND AND USE THEREOF IN THE TREATMENT OF A HYPERPROLIFERATIVE DISORDER - The invention provides combinations comprising GDC-0068 or GDC-0941, or a pharmaceutically acceptable salt thereof and ME-HD7945A. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer (e.g., triple negative breast cancer). | 2015-10-29 |
20150306217 | VACCINES AGAINST HPV - The present invention relates to therapeutic compounds, such as vaccines against human papillomavirus (HPV) and in particular to DNA vaccines against HPV16 or HPV18. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment of various HPV induced diseases, such as cancers and infectious diseases by application. | 2015-10-29 |
20150306218 | METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA - The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption. | 2015-10-29 |
20150306219 | SMALL MOLECULE INHIBITORS OF POLYNUCLEOTIDE KINASE/PHOSPHATASE, POLY(ADP-RIBOSE) POLYMERASE AND USES THEREOF - The present invention generally relates to use of compounds and compositions as a chemosensitizers and/or radiosensitizers and/or inhibitors of PNKP phosphatase activity. The present invention provides pharmaceutical combinations and/or a pharmaceutically acceptable salt thereof, kits containing such compounds and/composition and methods of using such compounds and/or compositions. | 2015-10-29 |
20150306220 | CONTROLLING THE ACTIVITY OF GROWTH FACTORS, PARTICULARLY TGF-BETA, IN VIVO - TGF-β growth factor and its latent complex are conjugated to magnetic micro- or nanoparticles and to magnetic micro- or nanodiscs. By exposing the resulting conjugates to magnetic fields, the TGF-β growth factor can be released from its latent complex in vivo, potentially making it useful in tissue engineering and regenerative medicine. And by exposing a conjugate of TGF-β growth factor and a magnetic particle to a sufficiently strong, radiofrequency magnetic field, the TGF-β growth factor can be denatured and thereby deactivated, potentially making it possible to avoid triggering tumorigenesis, atherosclerosis, fibrotic disease, and cancer. | 2015-10-29 |
20150306221 | Mixture of Betamethasone and Tranilast with a Transdermal Gel for Scar Treatment - The present disclosure relates to a synergistic mixture of betamethasone valerate and tranilast combined with a transdermal gel using skin permeation enhancement for application in scars for reducing or preventing the abnormal scar formation, specially keloids and hypertrophic scars. The disclosed synergistic mixture may exhibit permeation enhancing properties. The transdermal gel may include a mixture of silicone, phosphatidylcholine, pracaxi oil, and seje oil; one or more oils having essential fatty acids, behenic acid, oleic acid; one or more skin lipids; a butter having linoleic acid and linolenic acid; and solvents as transdermal penetration enhancers. | 2015-10-29 |
20150306222 | AQUEOUS LIQUID BROMFENAC COMPOSITION HAVING PRESERVATIVE EFFICACY - An aqueous liquid bromfenac composition containing (a) bromfenac or a salt thereof and (b) benzalkonium chloride, characterized by that the composition has preservative efficacy and that the concentration of (b) benzalkonium chloride is higher than 0.0005% and lower than 0.005%. | 2015-10-29 |
20150306223 | METHODS AND COMPOSITIONS FOR INACTIVATING ENVELOPED VIRUSES - Aspects of the invention provide therapeutic recombinant protein preparations and methods of preparing therapeutic recombinant protein, which methods include contacting recombinant protein preparations with zwitterionic detergent at or above critical micelle concentration of the detergent. | 2015-10-29 |
20150306224 | FORMULATION OF HUMAN ANTIBODIES FOR TREATING TNF-ALPHA ASSOCIATED DISORDERS - A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a pH of between about 4 and about 8, and enhanced stability. | 2015-10-29 |
20150306225 | Compositions for Delivering Drugs with Low Water Solubility - The present invention provides compositions comprising polymeric micelles containing a drug with low water solubility, wherein sterol rings of pegylated sterols and the drug form a hydrophobic portion and polyethylene glycol chains of the pegylated sterols forms a hydrophilic portion. The present invention also provides methods of preparing and using such compositions for delivering drug(s) with low water solubility to a subject in need thereof. | 2015-10-29 |
20150306226 | COMPOSITION - The present invention relates to compositions comprising compound (I) and processes for the preparation thereof. | 2015-10-29 |
20150306227 | POLYMERS INCLUDING ACTIVE AGENTS - Polymers are described herein comprising: a reaction product of a prepolymer solution including at least one macromer and at least one visualization agent; and an active agent electrostatically bound to the polymer filament or chemically bound to the at least one monomer; wherein the polymer filament does not include metallic support members. | 2015-10-29 |
20150306228 | Functionalized Water-Soluble Polyphosphazenes and Uses Thereof as Modifiers of Biological Agents - A polyphosphazene polymer which includes hydrophilic side groups and interacting side groups which are capable of bonding with a biological agent of interest. The bonding may be by non-covalent bonding. | 2015-10-29 |
20150306229 | MALLEABLE HYDROGEL HYBRIDS MADE OF SELF-ASSEMBLED PEPTIDES AND BIOCOMPATIBLE POLYMERS AND USES THEREOF - Hybrid hydrogels formed of a plurality of peptides that are capable of self-assembling into a hydrogel in an aqueous solution and a biocompatible polymer that is characterized by high swelling capability, high elasticity and low mechanical strength are disclosed, with exemplary hybrid hydrogels being formed of a plurality of aromatic dipeptides and hyaluronic acid. The hybrid hydrogels are characterized by controllable mechanical and biological properties which can be adjusted by controlling the concentration ratio of the peptides and the polymer, and which average the mechanical and biological properties of the peptides and the polymer. Processes of preparing the hydrogels and uses thereof in pharmaceutical, cosmetic or cosmeceutic applications such as tissue engineering and/or regeneration are further disclosed. | 2015-10-29 |